361 related articles for article (PubMed ID: 20606648)
21. Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo.
Kenny GD; Kamaly N; Kalber TL; Brody LP; Sahuri M; Shamsaei E; Miller AD; Bell JD
J Control Release; 2011 Jan; 149(2):111-6. PubMed ID: 20888381
[TBL] [Abstract][Full Text] [Related]
22. Glutamine addiction activates polyglutamine-based nanocarriers delivering therapeutic siRNAs to orthotopic lung tumor mediated by glutamine transporter SLC1A5.
Wang C; Wu J; Wang Z; Yang Z; Li Z; Deng H; Li L; Peng X; Feng M
Biomaterials; 2018 Nov; 183():77-92. PubMed ID: 30149232
[TBL] [Abstract][Full Text] [Related]
23. Glioma growth inhibition in vitro and in vivo by single chain variable fragments of the transferrin receptor conjugated to survivin small interfering RNA.
Wang F; Bai HR; Wang J; Bai YZ; Dou CW
J Int Med Res; 2011; 39(5):1701-12. PubMed ID: 22117970
[TBL] [Abstract][Full Text] [Related]
24. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor.
Chono S; Li SD; Conwell CC; Huang L
J Control Release; 2008 Oct; 131(1):64-9. PubMed ID: 18674578
[TBL] [Abstract][Full Text] [Related]
25. Targeted delivery of siRNA-generating DNA nanocassettes using multifunctional nanoparticles.
Cho YS; Lee GY; Sajja HK; Qian W; Cao Z; He W; Karna P; Chen X; Mao H; Wang YA; Yang L
Small; 2013 Jun; 9(11):1964-73. PubMed ID: 23292656
[TBL] [Abstract][Full Text] [Related]
26. Progress in microRNA delivery.
Zhang Y; Wang Z; Gemeinhart RA
J Control Release; 2013 Dec; 172(3):962-74. PubMed ID: 24075926
[TBL] [Abstract][Full Text] [Related]
27. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
28. Effect of Tumor Suppressor MiR-34a Loaded on ZSM-5 Nanozeolite in Hepatocellular Carcinoma: In Vitro and In Vivo Approach.
Salah Z; Abd El Azeem EM; Youssef HF; Gamal-Eldeen AM; Farrag AR; El-Meliegy E; Soliman B; Elhefnawi M
Curr Gene Ther; 2019; 19(5):342-354. PubMed ID: 31701846
[TBL] [Abstract][Full Text] [Related]
29. miR-335 directly, while miR-34a indirectly modulate survivin expression and regulate growth, apoptosis, and invasion of gastric cancer cells.
Yang B; Huang J; Liu H; Guo W; Li G
Tumour Biol; 2016 Feb; 37(2):1771-9. PubMed ID: 26318298
[TBL] [Abstract][Full Text] [Related]
30. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
[TBL] [Abstract][Full Text] [Related]
31. Novel Survivin-Targeted Small Interfering RNA Delivered by Nanoparticles.
Feng C; Wang T; Zhang Y; Qu K; Tang S
Am J Med Sci; 2017 Nov; 354(5):506-512. PubMed ID: 29173363
[TBL] [Abstract][Full Text] [Related]
32. Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression.
Shi S; Han L; Deng L; Zhang Y; Shen H; Gong T; Zhang Z; Sun X
J Control Release; 2014 Nov; 194():228-37. PubMed ID: 25220161
[TBL] [Abstract][Full Text] [Related]
33. Surface-modified LPD nanoparticles for tumor targeting.
Li SD; Huang L
Ann N Y Acad Sci; 2006 Oct; 1082():1-8. PubMed ID: 17145918
[TBL] [Abstract][Full Text] [Related]
34. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis.
Yao YD; Sun TM; Huang SY; Dou S; Lin L; Chen JN; Ruan JB; Mao CQ; Yu FY; Zeng MS; Zang JY; Liu Q; Su FX; Zhang P; Lieberman J; Wang J; Song E
Sci Transl Med; 2012 Apr; 4(130):130ra48. PubMed ID: 22517885
[TBL] [Abstract][Full Text] [Related]
35. Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles.
Li SD; Chono S; Huang L
J Control Release; 2008 Feb; 126(1):77-84. PubMed ID: 18083264
[TBL] [Abstract][Full Text] [Related]
36. Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo.
Das J; Das S; Paul A; Samadder A; Bhattacharyya SS; Khuda-Bukhsh AR
Toxicol Lett; 2014 Mar; 225(3):454-66. PubMed ID: 24440344
[TBL] [Abstract][Full Text] [Related]
37. Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer.
Mattheolabakis G; Ling D; Ahmad G; Amiji M
Pharm Res; 2016 Dec; 33(12):2943-2953. PubMed ID: 27528390
[TBL] [Abstract][Full Text] [Related]
38. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.
Han L; Tang C; Yin C
Biomaterials; 2014 May; 35(15):4589-600. PubMed ID: 24613049
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of cisplatin sensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmid expressing small hairpin RNA targeting Survivin.
Tian H; Liu S; Zhang J; Zhang S; Cheng L; Li C; Zhang X; Dail L; Fan P; Dai L; Yan N; Wang R; Wei Y; Deng H
J Biomed Nanotechnol; 2012 Aug; 8(4):633-41. PubMed ID: 22852473
[TBL] [Abstract][Full Text] [Related]
40. A Poly(Propyleneimine) Dendrimer-Based Polyplex-System for Single-Chain Antibody-Mediated Targeted Delivery and Cellular Uptake of SiRNA.
Tietze S; Schau I; Michen S; Ennen F; Janke A; Schackert G; Aigner A; Appelhans D; Temme A
Small; 2017 Jul; 13(27):. PubMed ID: 28544767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
